

	<b>More Severe Macromastia (N = 187)</b>	<b>Less Severe Macromastia (N = 188)</b>	<b>OR (95% CI)</b>	<b>P Value</b>
<b>Patient demographics, N (%)</b>				
Young age at surgery (<18.1 years)	105 (56.1)	88 (46.8)	1.46 (0.97-2.19)	.07
Overweight/obese status	150 (80.2)	98 (52.1)	3.72 (2.35-5.90)	<b>&lt;.001</b>
Racial/ethnic minority status	61 (44.5)	31 (20.0)	3.21 (1.91-5.39)	<b>&lt;.001</b>
<b>Pubertal history, N (%)</b>				
Precocious puberty (<8 years)*	6 (3.4)	7 (4.0)	0.81 (0.27-2.47)	.72
Early menarche (<11 years)	49 (26.2)	19 (10.1)	3.16 (1.78-5.62)	<b>&lt;.001</b>
<b>Gynecological/endocrine history, N (%)</b>				
Patient-reported gynecological/endocrine complaint	67 (35.8)	47 (25.0)	1.69 (1.08-2.64)	<b>.02</b>
Physician-diagnosed gynecological/endocrine disease	23 (12.3)	17 (9.0)	1.42 (0.73-2.75)	.30
<b>Social history, N (%)</b>				
Any recreational drug use	27 (14.4)	51 (27.1)	0.45 (0.27-0.76)	<b>.003</b>
Marijuana use	16 (8.6)	17 (9.0)	0.94 (0.46-1.92)	.87
Alcohol use	15 (8.0)	36 (19.1)	0.37 (0.19-0.70)	<b>.002</b>
Smoking and tobacco use	5 (2.7)	9 (4.8)	0.55 (0.18-1.66)	.29
<b>Family history, N (%)</b>				
Family history of macromastia	65 (34.8)	50 (26.6)	1.47 (0.95-2.29)	.09
First degree relative with macromastia	37 (19.8)	28 (14.9)	1.41 (0.82-2.42)	.21

Family history of breast cancer	52 (27.8)	59 (31.4)	0.84 (0.54-1.31)	.45
First degree relative with breast cancer	4 (2.1)	8 (4.3)	0.49 (0.15-1.66)	.25
<b>Medication use, N (%)</b>				
Corticosteroid use	24 (12.8)	32 (17.0)	0.72 (0.41-1.27)	.26
Non-steroidal inflammatory drug use	23 (12.3)	27 (14.4)	0.84 (0.46-1.52)	.56
Anti-epileptic/anti-convulsant use	13 (7.0)	6 (3.2)	2.27 (0.84-6.10)	.11
Antidepressant use	25 (13.4)	27 (14.4)	0.92 (0.51-1.65)	.78
Antipsychotic use	6 (3.2)	5 (2.7)	1.21 (0.36-4.05)	.75
Other psychotropic medication use	15 (8.0)	16 (8.5)	0.94 (0.45-1.96)	.86
Long-term antibiotic use	10 (5.3)	14 (7.4)	0.70 (0.30-1.62)	.41
Hormone therapy	14 (7.5)	8 (4.3)	1.82 (0.75-4.45)	.19
Antihistamine (H1) use	16 (8.6)	23 (12.2)	0.67 (0.34-1.32)	.25
Antihypertensive use	5 (2.7)	6 (3.2)	0.83 (0.25-2.78)	.77
Gastrointestinal medication use	7 (3.7)	10 (5.3)	0.69 (0.26-1.86)	.47
Antiretroviral use	2 (1.1)	1 (0.5)	2.02 (0.18-22.49)	.57
Vitamin A derivative use	4 (2.1)	1 (0.5)	4.09 (0.45-36.92)	.21

\*Thelarche data were unreported for 13 subjects.

**CI:** confidence interval; **OR:** odds ratio